Exclusive distribution agreement brings Point-Of-Care (POC) haematology diagnostics to new regions in the Middle East
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
The mAbxience partnership will enable Cipla to continue its ethos of ensuring equitable access to affordable, life-saving medication
Technology Development Board supports commercialisation of Metal Injection Molding of implants
AbbVie to present 30 abstracts demonstrating its leadership in neuroscience, including continued migraine treatment research across the spectrum of the disease, commitment to patients with advanced Parkinson's disease, and new studies in spasticity and cervical dystonia
Recommendation is based on pivotal data from the phase III POLARIX study
Data published in the prestigious journal ACS Central Science of the American Chemical Society
Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
Data from this study will support a submission to expand the use of atogepant to include preventive treatment of chronic migraine in the United States and additional submissions globally
It is also setting up laboratories in West Bengal, Assam, Bihar, Jharkhand and Orissa to comprehensively cater to the East India region
Subscribe To Our Newsletter & Stay Updated
